An Overview of Aducanumab for the Treatment of Alzheimer Disease

Pamela Spicer, senior analyst with Datamonitor Healthcare, said aducanumab is a once-monthly infusion with a 6-month titration schedule.

In a recent interview with Pharmacy Times, Pamela Spicer, senior analyst with Datamonitor Healthcare at Informa Pharma Intelligence, reviewed the approval of aducanumab and what pharmacists should know about its use in patients with Alzheimer disease. Spicer said aducanumab is a once-monthly infusion with a 6-month titration schedule. It has several notable adverse effects, including amyloid-related imaging abnormalities which should be monitored closely.